Analytical QbD (AQbD) promises to extend the rigour and benefits of QbD into the area of analytical method development. Stuart Wakefield, Director, Malvern Aimil Instruments, India, provides an introduction to the methodology involved and takes as an example the application of AQbD to the development of a laser diffraction particle sizing method
The application of Quality by Design (QbD) has become second nature to the pharmaceutical industry. The concept of scoping, understanding and controlling a pharma manufacturing process within the ‘design space’ is well-established. The FDA have encouraged the adoption of QbD by offering, in return, operational freedom within the design space. This enables a responsive approach to be understood but unavoidable variability and can substantially enhance manufacturing efficiency. Such gains prompt the question as to whether the principles enshrined in QbD are applicable to other processes, and analytical method development is now a focus. Just like conventional QbD, analytical QbD (AQbD) holds out the prize of flexibility, in contrast to the rigidity of Standard Operating Procedures (SOPs).
The FDA has already released guidance outlining the potential benefits that this flexibility might bring. The view is that the adoption of AQbD will support the development of robust analytical methods which will more easily transfer with the product, through scale-up, from site to site and indeed from instrument to instrument. This represents a considerable incentive for an industry so heavily reliant on rigorous analysis.
Introducing the concept of AQbD
The generally accepted definition of QbD, as presented in International Conference of Harmonisation document Q8(R2) (ICHQ8), is: ‘A systematic approach to development that begins with predefined objectives and emphasises product and process understanding, based on sound science and quality risk management.’ This central idea of a structured and rigorous approach to the development of a process has resonance in the development of analytical methodologies.
Conventional QbD begins with the identification of performance targets for the product, the Quality Target Product Profile (QTPP). This usually takes the form of a defined pharmacological or physical feature, such as the dissolution profile and disintegration time for an oral dosage form or bioequivalence to an innovator product. The next step is to identify the attributes and features which deliver the QTTP, the Critical Quality Attributes (CQAs). These are then controlled through knowledgeable manipulation of the Critical Process Parameters (CPPs), which define how the process is operated, and the Critical Material Attributes (CMAs), which are properties of the raw and intermediate ingredients.
For AQbD the starting point is identification of an Analytical Target Profile (ATP). This is the definition of what the analytical method is required to do, which is usually to measure a property that directly affects product quality. For instance, rate of dissolution has a substantial impact on product performance so determining particle size might be necessary to control product quality. Detailed consideration of the ATP identifies the reproducibility and accuracy which must be delivered for the analysis to fulfil its purpose.
The next step in AQbD is to determine an appropriate technique for analysis. Rarely is a measured parameter supplied exclusively by a single technique so the choices available must be considered carefully, with reference to the ATP. Once a technique has been selected, AQbD focusses on building a robust method by identifying critical method attributes and systematically assessing the risks and variability associated with the technique. This systematic study of risk factors may be supported by Design of Experiments (DOE) or Multi-Variate Analysis (MVA) tools and leads to scoping of the ‘design space’ for the analytical method, the Method Operable Design Region (MODR).
Once an MODR is defined that produces results which consistently meet ATP goals, appropriate methods of control are put in place and method validation carried out following ICH Q2. As with QbD, the entire AQbD workflow is held within a system of ‘Life Cycle Management,’ which implies a process of continuous improvement.
In going beyond simple SOP definitions to create an analytical design space, AQbD enables a responsive approach to the inherent variability encountered in day-to-day analysis, delivering robust methods for use throughout the pharma life cycle. It also has the potential to reduce the risks involved in analytical method transfer, where the root cause of failure usually stems from insufficient consideration of the operating environment and a failure to capture and transfer the information needed to deliver robust measurement.
AQbD in practice
The easiest way to understand AQbD is by considering a practical example. A suitable illustration is the application of AQbD in the development of a particle sizing method. Particle size is routinely measured across the pharma industry and laser diffraction is very often the technique of choice.
Define goals — Setting the ATP
‘…particle size analysis is not an objective in itself but a means to an end…”
H Heywood Proc, Ist Particle Size Annual conference September 1966
In an industrial setting, particle size is measured because it correlates with properties of a finished product or has an impact on the manufacturing process. To identify an ATP for a particle sizing method it is therefore vital to ask: “why is particle size being measured?”
To answer this question it is helpful to refer back to the QbD workflow. This enables an understanding of which CMA (solubility or content uniformity for example) or CPP (perhaps powder flowability) it is that particle size analysis is being used to control. This will establish whether or not particle size is a CQA for the product. ICHQ6A is very useful here since it supports a systematic assessment of whether or not a particle size specification is required [ICHQ6A]. In general particle size specification should be considered if a pharma product contains particles and if the size of those particles influences:
- Dissolution profile, solubility or bioavailability
- Content uniformity
If a particle size specification is required then this is the basis for an ATP. However, an ATP should outline not only which variable must be measured, but also why, and which attributes of the measurement — reproducibility and accuracy, for example — will define success. Defining the ATP also requires a consideration of the analytical technique that will be used and the specific metrics it will deliver. Laser diffraction is now the preferred choice for particle sizing in the micron range, in many instances, and is therefore the focus of this AQbD example.
Introducing laser diffraction
In laser diffraction particle size analysis, the particles in a sample are illuminated by light from a collimated laser beam which is then scattered by the particles present over a range of angles. The angle of this scattered light is proportional to its size.
Figure 2 shows a typical report from a laser diffraction analysis highlighting the metrics that the method supplies which can be used to set particle size distribution specifications. The most commonly used values are the percentiles Dv(10), Dv(50), and Dv(90), the size below which 10 per cent, 50 per cent and 90 per cent of the particle population falls respectively, on the basis of volume. Additionally, the mean particle diameters D[3,2] and D[4,3] which are based on surface area and volume respectively may also be used.
Develop the method – determining the CQAs for the analytical procedure
The ATP identifies what will be measured, for example, Dv(50) and Dv(90) to an accuracy of +/-3 per cent, to meet the stated purpose of the analysis. The next step is to look at what parameters must be controlled to meet this target performance: the CQAs of the method.
Figure 3 presents the relative potentials for error in particle sizing from three important sources: sampling; instrumentation; and dispersion. It is clear that errors resulting from dispersion and sampling are generally larger than the error associated with the instrument. Both sampling and dispersion are clearly highlighted as CQAs and must therefore be rigorously controlled.
The control of sampling begins with extracting the sample from the bulk, but extends through the analytical method to measurement time, which reflects how much of a gathered sample is actually analysed. When it comes to dispersion it is vital to refer back to the ATP to identify the purpose of the measurement. For instance, if the goal is to understand powder flowability then measuring the sample in its agglomerated state may give more relevant information. On the other hand if the intent is to control clinical features, such as solubility or bioavailability, then dispersing the material to its primary size is more beneficial.
In most cases primary particle size is the parameter of interest, and dispersion forms part of most laser diffraction analyses. Here there is a choice to be made between dry and liquid dispersion.
Assessing the options for sample dispersion
Liquid dispersion uses a wetting agent to reduce the forces of attraction between particles, and dispersion is induced by stirring and/or sonication. The use of a liquid dispersant makes this technique more complex and less environmentally favourable than dry measurement, especially for samples that are sensitive to water, the preferred dispersant. However, wet dispersion is both gentle and effective and therefore is well suited to fragile and friable samples that are prone to breakage/damage. It is also the dispersion method of choice when working with compounds where exposure needs to be tightly controlled.
Dry dispersion, a more physically intense process, involves entraining samples within a high-velocity air stream. Dispersion results from collisions between particles and/or between particles and a surface and the shear stress induced by the rapid acceleration and deceleration of particles . The advantages of dry dispersion are simplicity, speed and low environmental impact.
Ensuring complete dispersion, either wet or dry, is an essential element of laser diffraction analysis. This makes the parameters that control dispersion CPPs for the laser diffraction method – variables that directly impact data quality. The following example outlines how to scope the MODR for a wet dispersion but clearly the same process could be applied to a dry measurement. Clearly a wet or dry measurement will be followed in a typical AQbD project, rather than both.
Risk assessment: Scoping the MODR for liquid dispersion
In summary the development of a wet dispersion method involves:
- Choosing an appropriate dispersant
- Determining the amount of energy required to ensure complete dispersion
- Verifying the state of the dispersion using a reference technique such as imaging
Figure 4 shows a ‘fishbone’ risk assessment that summarises all the potential sources of variability that impact a wet method. Risk factors fall into three distinct groups: noise factors (green), control factors (orange) and experimental factors (red). It is the experimental factors that require systematic investigation to determine the MODR for the analytical method. The following experimental examples show how this can be achieved.
Sonication power/ time
Figure 5 shows the results from an experiment to investigate the effect of sonication on sample dispersion. Particle size is clearly reduced by sonication but there is an appreciable time taken to reach stability, a phenomenon that must be reflected in the developed method.
Sample quantity/ laser obscuration
Figure 6 shows data from experiments investigating the impact of laser obscuration, which is often taken as a measure of sample concentration. Laser diffraction systems do not directly report sample concentration. Instead users add sample to achieve a certain level of obscuration, which is the percentage of light intensity that is attenuated through absorption or multiple scattering by the particles, during measurement. However, obscuration depends not only on particle concentration, but also particle size. Achieving a specific obscuration with fine particles requires a much higher sample concentration than with larger particles because of the increase in scattering efficiency that occurs as particle size reduces.
The results from this experiment reflect these effects. For the sample containing larger particles, the reported particle size is independent of sample concentration. However for fines, a reduction in the reported particle size is observed above four per cent obscuration. At this point the sample concentration is so high that multiple scattering has begun to occur. With these finer particles a relatively low obscuration is required to approach the robustness achieved with the coarser sample.
Figure 7 shows the results of stirrer speed titration, an assessment of the impact of stirrer speed on measured particle size. Above 2500 rpm, particle size is stable indicating that the whole sample is in suspension. Below this speed, larger particles are settling and fine particles are being sampled disproportionately.
Figure 8 shows the results of an experiment to assess the impact of measurement time. If the duration of measurement is too short, then larger particles that are present in small numbers might be missed. For samples with broad distributions, measurement duration is especially important. These results show that measurement times in excess of 10 seconds provide consistent data in this case.
Control — method validation for particle size measurements
The final step in the AQbD process is to ensure that the necessary control is in place, that the method is validated. USP<1225> and the FDA’s latest Guidance for Industry for Analytical Procedures and Methods Validation both provide a list of analytical validation characteristics which should be considered when validating physical property methods. Stress is laid on a case-by-case assessment of the characteristics which should be considered, with the goal of determining that the procedure is suitable for use.
USP<1225> goes on to specify a generic approach for selecting the appropriate characteristics based on the category in which the technique in question falls, with the main characteristic for particle size analysis being precision. However, the specific use of the method and the characteristics of the material being analysed should be taken in to consideration before defining the most appropriate characteristics. These reference back to the ATP.
Both USP <429>, the USP general chapter relating to laser diffraction methods, and USP<1225> specify the importance of accuracy assessment to ensure optimum equipment performance prior to carrying out methods validation, and guidance is provided on how this should be achieved using standard reference materials. USP<429> also suggests that the sample concentration range should also be considered, so as to ensure that the measured particle size distribution is not affected by changes in concentration within the concentration range specified for the method.
Concentration range definition should be assessed on a case by case basis and will be highly dependent on the nature of the sample and the type of method being validated. Considering the method validation process, the following should be considered in confirming that a particle sizing method is fit for purpose:
- A system calibration (accuracy assessment) should be performed according to the manufacturer’s and/or the laboratory’s specification using a certified reference material.
- The precision and intermediate precision of the method should be assessed.
- The robustness of the method should be understood, with reference to the critical method attributes.
- Assurance should be provided that the data generated is reproducible and is effective in controlling the product’s quality.
Assessing precision involves seven measurements of the same sample. It therefore tests the consistency of the sampling and dispersion process. Intermediate precision is then assessed by considering different operators. Reproducibility is a broader concept that also encompasses multiple analytical systems, possibly across multiple laboratories on different company sites. The method robustness is defined with reference to the risk assessment stage of the AQbD process.
USP<429> and ISO13320: 2009 provide guidance as to the precision (repeatability) and reproducibility that particle sizing should deliver. However, the specifications are relatively broad and far closer tolerances may be set where necessary. At this point it is crucial to ensure that the precision and reproducibility match the requirements of the ATP rather than simply answer to regulatory guidance, since ultimately this will determine the success of the analytical technique across the lifetime of the product.
Precision is assessed by running the developed method a number of times on the same sample. Table 1 shows the results from this type of experiment, with the analyses conducted by a single operator.
In accordance with USP guidance more than six measurements are performed. The Coefficient of Variation (COV) is found to be within USP limits, with the slightly broader spread of results for the Dv10 and Dv90 bring attributed to dispersion and sampling respectively. Table 2 shows the results recorded when a different operator conducts the same series of analyses.
COV is again within the limits set by USP guidance. Performing the measurement a number of times with a range of different operators scopes the impact of operator variability and enables calculation of the intermediate precision, by pooling all of the results. Once precision has been validated to an acceptable level, attention can then turn to testing reproducibility, the precision of the method when used with fresh samples prepared by a different operator for example, or at different laboratories to complete the validation process.
Easing the analytical workload — tools that help with AQbD
Recent advances in analytical instrumentation, and associated software, can make a big difference when it comes to the application of AQbD. For example, some laser diffraction systems (such as the Mastersizer 3000, Malvern Instruments) have SOP player functions, which allow method development or validation testing to be automated. Using this tool, users can build measurement sequences around existing SOPs to enable rapid experimentation.
Malvern’s Data Quality tool for the Mastersizer 3000, for example, enables operators to critically assess measurement data and results during an analysis. Figure 9 shows an example output from this software. Advice is given relating to the measurement process (e.g. instrument cleanliness and alignment) and also the analysis process. The net result is to deliver Malvern expertise directly at the point of analysis in a way that that makes it possible to detect measurements that may be out of specification, and also to obtain the advice needed to optimise SOPs.
Laser diffraction is a well-established and highly automated technique. Arguably, tools that support the implementation of AQbD may be more advanced in this area than elsewhere. However, other instrumentation increasingly offers functionality that can be very helpful in AQbD. SOP-driven operation is now a standard feature in many of Malvern Instruments technologies such as Dynamic Light Scattering, Imaging and Rheological measurement systems and advancing SOP-driven operation, a valuable asset in AQbD related studies.
More than a decade ago Malvern Instruments broke new ground by delivering standard operating procedure-driven analysis in the Mastersizer 2000, helping to bring robust and reliable analysis to the pharma industry. Today, with the benefit of QbD experience, the strict adherence to SOPs has rightly been identified as an overly rigid approach to analysis. The advent of AQbD brings the promise of flexibility and an associated easing of method transfer that will ensure analytical methods are efficient and robust, and useful throughout the lifetime of an analytical product.